Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients.

Published on Aug 1, 2020in Lung Cancer4.702
· DOI :10.1016/J.LUNGCAN.2020.06.009
Weixiong Yang2
Estimated H-index: 2
(SYSU: Sun Yat-sen University),
Na You4
Estimated H-index: 4
(SYSU: Sun Yat-sen University)
+ 16 AuthorsChao Cheng5
Estimated H-index: 5
(SYSU: Sun Yat-sen University)
Abstract Objectives The application of circulating tumor DNA (ctDNA) monitoring after resection in pathologic(p) stage I lung adenocarcinoma (LUAD) patients remains controversial and it is of great clinical interest to decipher the difference of genetic features between ground-glass opacity (GGO) and solid nodules (non-GGO) subgroups. We aim to assess the utility of ctDNA in tracking early recurrence or metastasis following surgery and reveal the genetic differences between GGO and non-GGO. Materials and methods Tumor tissues and matched postoperative plasma samples were collected from a total of 82 (p)stage I LUAD patients. Comprehensive genomic profiling was performed using capture-based hybrid next generation sequencing by targeting 422 cancer relevant genes. Results EGFR and TP53 represent commonly mutated genes in this cohort of (p)stage I lung adenocarcinoma, followed by alterations in ALK, PIK3CA, STK11 and MYC. For a median follow-up period of 22.83 months after surgery, 65 out of 67 ctDNA-negative patients remained progression-free, while 3 out of 15 ctDNA-positive patients progressed [P = 0.040; positive predictive value = 0.20, 95% confidence interval (CI), 0.04-0.48; negative predictive value = 0.97, 95% CI, 0.9–1]. With time-dependent Cox regression analysis, we observed that ctDNA positivity significantly correlated with increased probability of early tumor recurrence or metastasis (P = 0.02, HR=8.5). Further comparison between GGO and non-GGO subgroups indicated the frequency of TP53 mutations in non-GGO was markedly higher than that in GGO (47% vs 21%, P  Conclusions Our longitudinal ctDNA monitoring data showed that undetectable ctDNA may predict low risk of tumor recurrence or metastasis in postoperative (p)stage I LUAD patients, while it requires further investigation on how robust the positive ctDNA results could predict tumor relapse in these patients. Clinical registration number NCT03172156.
📖 Papers frequently viewed together
25 Citations
20 Citations
3 Authors (M. Dorbeau, ..., F. Bibeau)
26 Citations
Background Lung adenocarcinomas (LUADs) that radiologically display as subsolid nodules (SSNs) exhibit more indolent biological behavior than solid LUADs. SSNs, commonly encompassing preinvasive and invasive but early-stage adenocarcinomas, can be categorised as pure ground-glass nodules (pGGNs) and part-solid nodules (PSNs). The genomic characteristics of SSNs remain poorly understood. Methods We subjected 154 SSN samples from 120 treatment-naive Chinese patients to whole exome sequencing. Clin...
11 CitationsSource
#1Tomohiro MiyoshiH-Index: 14
#2Keiju AokageH-Index: 24
Last. Masahiro TsuboiH-Index: 49
view all 6 authors...
Background A ground-glass opacity (GGO) component on chest computed tomography (CT) pathologically corresponds to lepidic adenocarcinoma. However, the precise correspondence relation and the prognostic significance remains unclear in patients with pathologic stage IA lung adenocarcinoma. Methods We retrospectively reviewed the clinicopathologic features of 809 consecutive patients with pathologic stage IA lung adenocarcinoma who underwent complete resection between 2003 and 2014. We evaluated th...
14 CitationsSource
#1Aritoshi Hattori (Juntendo University)H-Index: 15
#2Shunki Hirayama (Juntendo University)H-Index: 5
Last. Kenji Suzuki (Juntendo University)H-Index: 69
view all 7 authors...
Abstract Introduction We evaluated differences in the clinicopathologic characteristics and prognosis based on the presence of ground glass opacity (GGO) components in small-sized lung adenocarcinoma. Methods We retrospectively investigated 634 lung adenocarcinomas classed as c-stage IA in the eighth edition TNM classification. Staging was defined according to the solid component size measured by thin-section computed tomography. All tumors were grouped into either a GGO or solid group, based on...
41 CitationsSource
#1Christopher Abbosh (UCL: University College London)H-Index: 14
#2Nicolai Juul Birkbak (UCL: University College London)H-Index: 42
Last. Charles Swanton (UCL: University College London)H-Index: 99
view all 3 authors...
Circulating tumour DNA (ctDNA) refers to the fraction of cell-free DNA in a patient’s blood that originates from a tumour. Advances in DNA sequencing technologies and our understanding of the molecular biology of tumours have resulted in increased interest in exploiting ctDNA as a tool to facilitate earlier detection of cancer and thereby improve therapeutic outcomes by enabling early intervention. ctDNA analysis might also have utility in the adjuvant therapeutic setting by enabling the identif...
123 CitationsSource
#1Yeon koo Kang (SNU: Seoul National University)H-Index: 4
#2Yoo Sung Song (Seoul National University Bundang Hospital)H-Index: 11
Last. Sang Eun Kim (SNU: Seoul National University)H-Index: 30
view all 7 authors...
Abstract Purpose In the management of non-small cell lung cancer (NSCLC), the prognostic stratification of stage I tumors without indication of adjuvant therapy, remains to be elucidated in order to better select patients who can benefit from additional therapies. We aimed to stratify the prognosis of patients with stage I NSCLC adenocarcinoma using clinicopathologic factors and F-18 FDG PET. Materials and methods We retrospectively enrolled 128 patients with stage I NSCLC without any high-risk ...
10 CitationsSource
#1Matthew H. Bailey (WashU: Washington University in St. Louis)H-Index: 15
#2Collin Tokheim (Johns Hopkins University)H-Index: 16
Last. Li DingH-Index: 113
view all 45 authors...
Summary Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on large datasets are few. We report a PanCancer and PanSoftware analysis spanning 9,423 tumor exomes (comprising all 33 of The Cancer Genome Atlas projects) and using 26 computational tools to catalog driver genes and mutations. We identify 299 driver genes with implications regarding their anatomical si...
1,015 CitationsSource
#1Jason D. Merker (Stanford University)H-Index: 23
#2Geoffrey R. Oxnard (Harvard University)H-Index: 60
Last. Nicholas C. TurnerH-Index: 64
view all 17 authors...
PurposeClinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from ASCO and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research.MethodsAn Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including pre-analytical variables, analytical validity, interpretation and reporting, and clinical validity and u...
359 CitationsSource
#1Zhe Yang (SDU: Shandong University)H-Index: 2
#2Nong YangH-Index: 13
Last. Caicun Zhou (Tongji University)H-Index: 68
view all 13 authors...
Background: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-positive non–small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs. Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients. However, the remaining resistance mechanisms are largely unknown. Methods: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-releva...
179 CitationsSource
Earlier detection is key to reducing cancer deaths. Here we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1,005 patients with non-metastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities rang...
1,085 CitationsSource
#1Aadel A. Chaudhuri (Stanford University)H-Index: 22
#2Jacob J. Chabon (Stanford University)H-Index: 19
Last. Maximilian Diehn (Stanford University)H-Index: 63
view all 27 authors...
Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization of adjuvant therapies. Here we apply Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) circulating tumor DNA (ctDNA) analysis to 255 samples from 40 patients treated with curative intent for stage I-III lung cancer and 54 healthy adults. In 94% of evaluable patients experiencing recurrence, ctDNA was detectable in the first post-treatment blood s...
313 CitationsSource
Cited By5
Colorectal cancer is the third most common cancer worldwide, and its incidence continues to grow. Approximately one-third of patients with colorectal cancer develop liver metastases during the natural course of disease. Complete surgical resection is associated with very low mortality in colorectal liver metastasis patients, but only a small fraction of colorectal liver metastasis patients fulfill the selection criteria for surgical treatment. We herein describe a high-risk stage-IV rectal carci...
#1Chao Zhou (SJTU: Shanghai Jiao Tong University)H-Index: 1
Last. Chang ChenH-Index: 19
view all 5 authors...
Background This study aimed to investigate the potential cytological effects and molecular mechanisms of β-catenin (CTNNB1) S37C mutation in lung adenocarcinoma (LUAD). Methods CTNNB1 with S37C mutation were transfected into LUAD cell lines. The expression of β-catenin were determined using Western blot. Cell proliferation and migration were detected using cell counting kit-8 (CCK-8) assay and wound healing assay, respectively. Transcriptome sequencing was performed on LUAD cells with CTNNB1 S37...
#1Li Ma (Capital Medical University)H-Index: 7
#2Haoyang Li (Capital Medical University)H-Index: 1
Last. Jinghui Wang (Capital Medical University)H-Index: 12
view all 16 authors...
Purpose: Circulating cell-free DNA (cfDNA) level has been demonstrated to be associated with efficacy in first generation EGFR TKIs in non-small cell lung cancer (NSCLC). However, the role of dynamic cfDNA analysis using next-generation sequencing (NGS) in patients with subsequent third-generation EGFR-TKIs remains unclear. Methods: From 2016 to 2019, 81 NSCLC patients with EGFR T790M mutation either in tissue or plasma who received third-generation EGFR TKIs treatment were enrolled. CfDNA were ...
1 CitationsSource
Background Gastric cancer (GC) is confronted with limited options for precision medicine. Human epidermal growth factor receptor 2 (HER2) is the principal druggable target of GC, yet proper biomarkers for response/resistance prediction remain unveiled. Methods From 40 GC patients received HER2-targeted therapy, a total of 327 peripheral blood plasma specimens was collected including baseline and treatment time points. Circulating tumor DNA (ctDNA) was extracted and sequenced with a target panel ...
2 CitationsSource
#1Meiying Cui (Zhengzhou University)H-Index: 1
#2Yuchen Han (Shanghai Chest Hospital)H-Index: 1
Last. Guozhong Jiang (Zhengzhou University)H-Index: 8
view all 11 authors...
ROS1 gene rearrangements have been reported in diverse cancer types including non-small-cell lung cancer (NSCLC), and with a notably higher prevalence in lung adenocarcinoma. The tyrosine kinase inhibitors, crizotinib, lorlatinib, and entrectinib, have demonstrated favorable efficacy in treating ROS1-rearranged NSCLCs. Herein, we retrospectively reviewed 17 158 NSCLC patients whose tumor specimen and/or circulating cell-free DNA underwent comprehensive genomic profiling. A total of 258 unique pa...
2 CitationsSource